|
|
| | TOPOTECAN-D6 Basic information |
| Product Name: | TOPOTECAN-D6 | | Synonyms: | TOPOTECAN-D6;(4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[346-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;SKF-104864A-d6;(4S)-10-[(Dimethylamino-d6)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3’,4’,6-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;Hycamtin-d6;NSC-609669-d6;(4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;[2H6]-Topotecan | | CAS: | 1044904-10-0 | | MF: | C23H23N3O5 | | MW: | 421.45 | | EINECS: | | | Product Categories: | Heterocycles;Isotope Labelled Compounds;Inhibitors;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals | | Mol File: | 1044904-10-0.mol |  |
| | TOPOTECAN-D6 Chemical Properties |
| Melting point | 213-218°C (dec) | | storage temp. | -20°C Freezer | | solubility | aqueous acid: soluble; DMSO: slightly; Methanol: soluble | | form | A solid | | color | Light yellow to yellow | | Stability: | Hygroscopic | | CAS DataBase Reference | 1044904-10-0 |
| | TOPOTECAN-D6 Usage And Synthesis |
| Description | Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin . Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay. Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively). Formulations containing topotecan have been used in the treatment of small-cell lung cancer. | | Chemical Properties | Light Yellow to Greenish Powder | | Uses | Labelled Topotecan. A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic | | Uses | Labelled Topotecan (T542500). A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. | | References | [1] ROTHENBERG M L. Topoisomerase I inhibitors: Review and update[J]. Annals of Oncology, 1997, 8 9: Pages 837-855. DOI: 10.1023/a:1008270717294
[2] J DANCEY EA E. Current perspectives on camptothecins in cancer treatment[J]. British Journal of Cancer, 1996, 74 3: 327-338. DOI: 10.1038/bjc.1996.362
[3] JHM SCHELLENS. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor[J]. British Journal of Cancer, 1996, 73 10: 1268-1271. DOI: 10.1038/bjc.1996.243
[4] GISELA CACERES. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.[J]. Anti-Cancer Drugs, 2003, 14 7: 569-574. DOI: 10.1097/00001813-200308000-00010 |
| | TOPOTECAN-D6 Preparation Products And Raw materials |
|